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Introduction {#jdi13116-sec-0005}
============

Diabetic kidney disease is a major cause of end‐stage renal failure in many countries[1](#jdi13116-bib-0001){ref-type="ref"}, [2](#jdi13116-bib-0002){ref-type="ref"}, and approximately 16,000 patients with diabetic kidney disease undergo dialysis in Japan each year[3](#jdi13116-bib-0003){ref-type="ref"}. Microalbuminuria is an important clinical indicator to diagnose the early stage of diabetic nephropathy. Furthermore, albuminuria is well known to be a risk for cardiovascular diseases. Estimated glomerular filtration rate (eGFR) is widely used to estimate the renal function of diabetes patients. A variety of data have been reported on the incident rate of albuminuria and renal dysfunction in diabetes patients. The difference of the data might be caused by ethnicity, study protocol, sample size and method for measurement of albuminuria. It is well known that low eGFR is found in some normoalbuminuric diabetes patients, suggesting that different factors might contribute to albuminuria or deterioration of renal function.

The aim of the present study was to analyze the recent prevalence of albuminuria and renal dysfunction, and risk factors in Japanese patients with type 1 and type 2 diabetes using baseline data of the Japan Diabetes Complication and its Prevention prospective (JDCP) study, which is a large‐scale, prospective observational study of Japanese diabetes patients[4](#jdi13116-bib-0004){ref-type="ref"}, [5](#jdi13116-bib-0005){ref-type="ref"}, [6](#jdi13116-bib-0006){ref-type="ref"}, [7](#jdi13116-bib-0007){ref-type="ref"} carried out by the Japan Diabetes Society.

Methods {#jdi13116-sec-0006}
=======

Participants {#jdi13116-sec-0007}
------------

We used the baseline data of the JDCP study. The details of the JDCP study were previously described[4](#jdi13116-bib-0004){ref-type="ref"}, [5](#jdi13116-bib-0005){ref-type="ref"}, [6](#jdi13116-bib-0006){ref-type="ref"}, [7](#jdi13116-bib-0007){ref-type="ref"}. In brief, the JDCP study is a multicenter prospective observational cohort study with a 5‐year follow‐up period. Participants in the JDCP study are men and women aged 40--75 years with type 1 and type 2 diabetes who are treated as outpatients at participating institutions. The JDCP study is designed to assess the prevalence of diabetic complications, the status of treatment and management of diabetes, and the risk factors related to the onset and/or progression of diabetic complications, and thus obtaining results from the JDCP study are expected to provide important therapeutic insights into the management of type 1 and type 2 diabetes, particularly for the prevention and treatment of diabetic complications. A total of 7,700 participants were enrolled between June 2007 and November 2009 from university hospitals, secondary or tertiary hospitals, and clinics where diabetologists reside (total 464 clinics).

The inclusion criteria were as follows: (i) patients with type 1 and type 2 diabetes; and (ii) patients aged ≥40 to \<75 years. The exclusion criteria were: (i) cannot attend the hospital or clinic regularly; (ii) have proliferative diabetic retinopathy, (iii) undergoing dialysis; (iv) diagnosed with a malignant disease 5 years before registration; and (v) judged to be ineligible for this study by an attending physician.

The 6,338 patients with type 1 or type 2 diabetes who met the study eligibility criteria were registered between July 2007 and September 2011. In the current study, we used the baseline data of 355 patients with type 1 diabetes and 5,194 patients with type 2 diabetes. The JDCP study was approved by the Japan Diabetes Society Ethics Review Committee for Scientific Surveys and Studies, and by the ethics committee and institutional review board of each site.

Data collection {#jdi13116-sec-0008}
---------------

Data were collected as previously described[4](#jdi13116-bib-0004){ref-type="ref"}, [5](#jdi13116-bib-0005){ref-type="ref"}, [6](#jdi13116-bib-0006){ref-type="ref"}. The urinary albumin‐to‐creatinine ratio (UACR) was measured twice yearly in spot urine samples, and mean values were categorized as follows: normoalbuminuria (UACR \<30 mg/gCr), microalbuminuria (UACR ≥30 mg/gCr and \<300 mg/gCr) or macroalbuminuria (UACR ≥300 mg/gCr). The eGFR was calculated using the modified Modification of Diet in Renal Disease formula[8](#jdi13116-bib-0008){ref-type="ref"}.

Statistical analysis {#jdi13116-sec-0009}
--------------------

Continuous variables were expressed as the mean ± standard deviation, and categorical variables were shown as the number or percentages. The variable urinary albumin excretion rate was converted into a natural logarithm. The Shapiro--Wilk test was used for Gaussian distribution of continuous variables. A comparison between the two groups was analyzed by a Student\'s *t*‐test for continuous variables, and a χ^2^‐test was used for frequency. A binomial logistic regression analysis was used to investigate independent contributing factors for eGFR \<60 mL/min/1.73 m^2^ or albuminuria. We used the IBM SPSS Statistics 22 software program (IBM, Armonk, NY, USA) and the StatFlex version 6.0 software program (Artech Co., Osaka, Japan) for statistical analyses.

Results {#jdi13116-sec-0010}
=======

Data of albuminuria and eGFR of patients with type 1 and type 2 diabetes are shown in Table [1](#jdi13116-tbl-0001){ref-type="table"}. The prevalence of microalbuminuria (30--299 mg/gCr) and macroalbuminuria (≥300 mg/gCr) was 15.2% (54/355) and 3.1% (11/355) in type 1 diabetes patients, and 25.0% (1,298/5,194) and 5.1% (265/5,194) in type 2 diabetes patients. The proportion of renal dysfunction (eGFR \<60 mL/min/1.73 m^2^) was 9.9% (35/355) in type 1 diabetes patients, and 15.3% (797/5,194) in type 2 diabetes patients. The proportion of patients with renal dysfunction (eGFR \<60 mL/min/1.73 m^2^) without albuminuria (normoalbuminuria) was 7.3% (26/355) in type 1 diabetes patients, and 9.0% (467/5,194) in type 2 diabetes patients.

###### 

Number of type 1 and type 2 diabetes patients classified by estimated glomerular filtration rate and albuminuria

  CKD stage                   Total, *n* = 355 (100%)   Normoalbuminuria, *n* = 290 (81.7%)   Microalbuminuria, *n* = 54 (15.2%)   Macroalbuminuria, *n* = 11 (3.1%)
  --------------------------- ------------------------- ------------------------------------- ------------------------------------ -----------------------------------
  Type 1 diabetes                                                                                                                  
  Stage 1 (eGFR ≥90)          104 (29.3%)               82 (23.1%)                            21 (5.9%)                            1 (0.3%)
  Stage 2 (60 ≤ eGFR \< 90)   216 (60.8%)               182 (51.3%)                           27 (7.6%)                            7 (2.0%)
  Stage 3 (30 ≤ eGFR \< 60)   34 (9.6%)                 26 (7.3%)                             6 (1.7%)                             2 (0.6%)
  Stage 4 (15 ≤ eGFR \< 30)   1 (0.3%)                  0 (0.0%)                              0 (0.0%)                             1 (0.3%)
  Stage 5 (eGFR \<15)         0 (0.0%)                  0 (0.0%)                              0 (0.0%)                             0 (0.0%)

  CKD stage                   Total, *n* = 5,194 (100%)   Normoalbuminuria, *n* = 3,631 (69.9%)   Microalbuminuria, *n* = 1,298 (25.0%)   Macroalbuminuria, *n* = 265 (5.1%)
  --------------------------- --------------------------- --------------------------------------- --------------------------------------- ------------------------------------
  Type 2 diabetes                                                                                                                         
  Stage 1 (eGFR ≥90)          1,159 (22.3%)               788 (15.2%)                             327 (6.3%)                              44 (0.8%)
  Stage 2 (60 ≤ eGFR \< 90)   3,238 (62.3%)               2,376 (45.7%)                           759 (14.6%)                             103 (2.0%)
  Stage 3 (30 ≤ eGFR \< 60)   763 (14.7%)                 460 (8.9%)                              209 (4.0%)                              94 (1.8%)
  Stage 4 (15 ≤ eGFR \< 30)   27 (0.5%)                   6 (0.1%)                                3 (0.1%)                                18 (0.3%)
  Stage 5 (eGFR \<15)         7 (0.1%)                    1 (0.0%)                                0 (0.0%)                                6 (0.1%)

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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Clinical data of the patients with type 1 and type 2 diabetes are shown in Tables [2](#jdi13116-tbl-0002){ref-type="table"} and [3](#jdi13116-tbl-0003){ref-type="table"}. Duration of diabetes, past history or presence of hypertension, systolic blood pressure and the rate of prescription of angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were higher in type 1 diabetes patients with micro‐ or macroalbuminuria as compared with normoalbuminuria (Table [2](#jdi13116-tbl-0002){ref-type="table"}). The parameters that were increased in type 2 diabetes patients with micro‐ or macroalbuminuria were age, proportion of insulin therapy, duration of diabetes, past history or presence of hypertension and dyslipidemia, bodyweight, body mass index (BMI), waist circumference, glycated hemoglobin (HbA1c), blood glucose level, fasting immunoreactive insulin level, blood pressure, the level of total cholesterol, non‐high‐density lipoprotein cholesterol and triglycerides, serum creatinine level, and the rate of prescription of ACE inhibitors or ARBs. High‐density lipoprotein cholesterol and eGFR were lower in type 2 diabetes patients with albuminuria (Table [3](#jdi13116-tbl-0003){ref-type="table"}).

###### 

Albuminuria and clinical data in patients with type 1 diabetes

  Characteristics                   *n*   Normoalbuminuria (*n* = 290)   Micro‐ or macroalbuminuria (*n* = 65)   *P*‐value
  --------------------------------- ----- ------------------------------ --------------------------------------- -----------
  Age (years)                       355   56 ± 9                         58 ± 8                                  0.117
  Male (%)                          355   43.4                           46.2                                    0.691
  Duration of diabetes (years)      353   11 ± 8                         15 ± 11                                 0.009
  Past history or presence of                                                                                    
  Hypertension (%)                  355   19.3                           41.5                                    \<0.001
  Dyslipidemia (%)                  355   25.2                           29.2                                    0.500
  None (%)                          355   48.3                           35.4                                    0.059
  Regular alcohol intake (%)        354   25.6                           26.2                                    0.927
  Smoker, past/current (%)          354   37.0                           36.9                                    0.988
  Bodyweight (kg)                   355   57.0 ± 9.6                     55.8 ± 10.8                             0.483
  BMI (kg/m^2^)                     354   22.1 ± 2.9                     21.9 ± 3.1                              0.581
  Waist circumference (cm)          329   78.2 ± 9.2                     77.5 ± 9.2                              0.547
  HbA1c (%)                         353   7.7 ± 1.4                      8.0 ± 1.6                               0.215
  FPG (mg/dL)                       88    134.7 ± 62.2                   129.6 ± 59.6                            0.724
  PPPG (mg/dL)                      310   173.9 ± 88.3                   162.4 ± 82.6                            0.332
  Systolic blood pressure (mmHg)    352   124 ± 15                       131 ± 18                                0.002
  Diastolic blood pressure (mmHg)   352   72 ± 10                        74 ± 11                                 0.106
  Lipid profiles (mg/dL)                                                                                         
  Total cholesterol                 331   198.1 ± 27.4                   201.0 ± 38.2                            0.707
  LDL cholesterol                   333   108.1 ± 22.8                   106.8 ± 30.3                            0.503
  HDL cholesterol                   350   72.3 ± 16.9                    74.2 ± 22.5                             0.819
  Non‐HDL cholesterol               326   125.5 ± 23.8                   127.2 ± 33.2                            0.869
  Triglycerides                     157   83.1 ± 46.0                    86.6 ± 49.6                             0.860
  Serum creatinine (mg/dL)          355   0.7 ± 0.1                      0.7 ± 0.2                               0.674
  eGFR (mL/min/1.73 m^2^)           355   81.1 ± 16.5                    81.1 ± 19.9                             0.666
  ACEIs or ARBs (%)                 355   17.6                           40.0                                    \<0.001

Data are the mean ± standard deviation, or percentages. ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin‐receptor blockers; BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PPPG, postprandial plasma glucose.
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###### 

Albuminuria and clinical data in patients with type 2 diabetes

                                    *n*     All (*n* = 5,194)   Normoalbuminuria (*n* = 3,631)   Micro‐ or macroalbuminuria (*n* = 1,563)   *P*‐value
  --------------------------------- ------- ------------------- -------------------------------- ------------------------------------------ -----------
  Age (years)                       5,194   61 ± 8              61 ± 8                           62 ± 8                                     \<0.001
  Male (%)                          5,194   59.1                59.0                             59.4                                       0.798
  Diet/tablet/insulin (%)           5,187   10/62/27            12/64/25                         7/60/33                                    \<0.001
  Duration of diabetes (years)      5,122   11 ± 8              10 ± 8                           12 ± 9                                     \<0.001
  Past history or presence of                                                                                                               
  Hypertension (%)                  5,194   46.9                42.4                             57.5                                       \<0.001
  Dyslipidemia (%)                  5,194   48.5                47.3                             51.4                                       0.006
  None (%)                          5,194   23.0                24.8                             18.7                                       \<0.001
  Regular alcohol intake (%)        5,180   38.4                38.4                             38.2                                       0.839
  Smoker, past or current (%)       5,177   38.1                38.2                             37.9                                       0.818
  Bodyweight (kg)                   5,134   63.8 ± 12.1         63.2 ± 11.9                      65.2 ± 12.4                                \<0.001
  BMI (kg/m^2^)                     5,131   24.5 ± 3.9          24.2 ± 3.8                       25.2 ± 4.0                                 \<0.001
  Waist circumference (cm)          4,941   86.3 ± 10.4         85.6 ± 10.2                      88.1 ± 10.5                                \<0.001
  HbA1c (%)                         5,185   7.4 ± 1.3           7.3 ± 1.2                        7.6 ± 1.4                                  \<0.001
  FPG (mg/dL)                       2,096   135.3 ± 37.5        133.6 ± 35.2                     139.3 ± 42.3                               0.017
  PPPG (mg/dL)                      4,304   160.7 ± 58.6        156.4 ± 55.7                     170.5 ± 63.6                               \<0.001
  Fasting IRI (μU/mL)               1,061   7.9 ± 14.2          7.6 ± 12.4                       8.8 ± 17.8                                 \<0.001
  Systolic blood pressure (mmHg)    5,156   130 ± 15            128 ± 15                         134 ± 15                                   \<0.001
  Diastolic blood pressure (mmHg)   5,156   75 ± 10             74 ± 10                          76 ± 11                                    \<0.001
  Lipid profiles (mg/dL)                                                                                                                    
  Total cholesterol                 4,993   194.7 ± 33.1        193.9 ± 31.9                     196.8 ± 35.8                               0.047
  LDL cholesterol                   5,036   112.7 ± 28.1        112.2 ± 27.2                     113.9 ± 30.0                               0.164
  HDL cholesterol                   5,142   57.4 ± 15.8         58.0 ± 15.9                      56.0 ± 15.3                                \<0.001
  Non‐HDL cholesterol               4,946   137.5 ± 33.1        136.0 ± 31.9                     140.9 ± 35.6                               \<0.001
  Triglycerides                     2,507   125.9 ± 83.6        120.5 ± 76.0                     137.8 ± 97.4                               \<0.001
  Serum creatinine (mg/dL)          5,194   0.8 ± 0.3           0.7 ± 0.2                        0.8 ± 0.4                                  \<0.001
  eGFR (mL/min/1.73 m^2^)           5,194   77.3 ± 18.7         78.0 ± 17.1                      75.7 ± 22.0                                \<0.001
  ACEIs or ARBs (%)                 5,188   39.2                34.4                             50.4                                       \<0.001

Data are the mean ± standard deviation, or percentages. ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin‐receptor blockers; BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; IRI, immunoreactive insulin; LDL, low‐density lipoprotein; PPPG, postprandial plasma glucose.

John Wiley & Sons, Ltd

In contrast, the parameters that were increased in type 2 diabetes patients with renal dysfunction (eGFR \<60 mL/min/1.73 m^2^) were age, proportion of insulin therapy, duration of diabetes, past history or presence of hypertension and dyslipidemia, bodyweight, BMI, waist circumference, fasting immunoreactive insulin level, triglycerides level, urinary albumin‐to‐creatinine ratio, and the rate of prescription of ACE inhibitors or ARBs (Table [4](#jdi13116-tbl-0004){ref-type="table"}). The proportion of regular alcohol intake, HbA1c and blood glucose level, the level of total cholesterol, and high‐density lipoprotein cholesterol were lower in type 2 diabetes patients with renal dysfunction. Age was higher in type 1 diabetes patients with renal dysfunction ([Table S1](#jdi13116-sup-0001){ref-type="supplementary-material"}).

###### 

Estimated glomerular filtration rate and clinical data in patients with type 2 diabetes

                                    *n*           eGFR ≥60 mL/min/1.73 m^2^ (*n* = 4,397)   eGFR \<60 mL/min/1.73 m^2^ (*n* = 797)   *P*‐value
  --------------------------------- ------------- ----------------------------------------- ---------------------------------------- -----------
  Age (years)                       5,194         61 ± 8                                    65 ± 7                                   \<0.001
  Male (%)                          5,194         58.9                                      60.2                                     0.485
  Diet/tablet/insulin (%)           5,187         11/63/26                                  8/61/31                                  0.005
  Duration of diabetes (years)      5,122         10 ± 8                                    12 ± 9                                   \<0.001
  Past history or presence of                                                                                                        
  Hypertension (%)                  5,194         44.1                                      62.5                                     \<0.001
  Dyslipidemia (%)                  5,194         47.3                                      55.6                                     \<0.001
  None (%)                          5,194         24.8                                      13.0                                     \<0.001
  Regular alcohol intake (%)        5,180         39.4                                      32.7                                     \<0.001
  Smoker, past or current (%)       5,177         38.0                                      38.8                                     0.691
  Bodyweight (kg)                   5,134         63.7 ± 12.1                               64.7 ± 11.9                              0.020
  BMI (kg/m^2^)                     5,131         24.4 ± 3.9                                25.0 ± 3.9                               \<0.001
  Waist circumference (cm)          4,941         86.0 ± 10.3                               88.1 ± 10.4                              \<0.001
  HbA1c (%)                         5,185         7.4 ± 1.3                                 7.3 ± 1.2                                \<0.001
  FPG (mg/dL)                       2,096         136.1 ± 37.9                              130.5 ± 35.0                             0.008
  PPPG (mg/dL)                      4,304         161.8 ± 59.2                              154.9 ± 54.5                             0.006
  Fasting IRI (μU/mL)               1,061         7.8 ± 14.5                                8.8 ± 12.1                               0.004
  Systolic blood pressure (mmHg)    5,156         130 ± 15                                  131 ± 16                                 0.154
  Diastolic blood pressure (mmHg)   5,156         75 ± 10                                   74 ± 10                                  \<0.001
  Lipid profiles (mg/dL)                                                                                                             
  Total cholesterol                 4,993         195.2 ± 32.8                              192.0 ± 34.8                             0.009
  LDL cholesterol                   5,036         113.1 ± 28.0                              110.6 ± 28.2                             0.052
  HDL cholesterol                   5,142         57.9 ± 15.7                               54.4 ± 15.9                              \<0.001
  Non‐HDL cholesterol               4,946         137.5 ± 32.7                              137.2 ± 35.3                             0.656
  Triglycerides (mg/dL)             2,507         124.2 ± 85.7                              135.3 ± 70.3                             \<0.001
  UACR (mg/gCr)                     4,968         45.2 ± 202.8                              103.9 ± 463.8                            \<0.001
  Log UACR                          1.21 ± 0.55   1.35 ± 0.66                                                                        
  ACEIs or ARBs (%)                 5,188         58.9                                      60.2                                     \<0.001

Data are the mean ± standard deviation, or percentages. ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin‐receptor blockers; BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; IRI, immunoreactive insulin; LDL, low‐density lipoprotein; PPPG, postprandial plasma glucose; UACR, urinary albumin‐to‐creatinine ratio.
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Factors related to albuminuria and renal dysfunction in patients with type 1 and type 2 diabetes by logistic regression model are shown in Tables [5](#jdi13116-tbl-0005){ref-type="table"} and [S2](#jdi13116-sup-0001){ref-type="supplementary-material"}. The duration of diabetes (95% confidence interval (CI) 1.010--1.071, *P* = 0.009) and past history or presence of hypertension (95% CI 1.324--4.846, *P* = 0.005) were positively related to micro‐ and macroalbuminuria, and age (95% CI 1.062--1.182, *P* \< 0.001), and duration of diabetes (95% CI 1.006--1.088, *P* = 0.023) was positively related to low eGFR in patients with type 1 diabetes ([Table S2](#jdi13116-sup-0001){ref-type="supplementary-material"}). Factors positively related to albuminuria in type 2 diabetes were age (95% CI 1.002--1.020, *P* = 0.017), duration of diabetes (95% CI 1.011--1.027, *P* \< 0.001), past history or presence of hypertension (95% CI 1.455--1.892, *P* \< 0.001), BMI (95% CI 1.033--1.069, *P* \< 0.001), HbA1c (95% CI 1.175--1.295, *P* \< 0.001) and eGFR (95% CI 1.301--1.819, *P* \< 0.001). In contrast, positively related factors to renal dysfunction were male sex (95% CI 1.260--1.828, *P* \< 0.001), age (95% CI 1.062--1.089, *P* \< 0.001), duration of diabetes (95% CI 1.006--1.026, *P* = 0.002), past history or presence of dyslipidemia (95% CI 1.075--1.495, *P* = 0.005) and hypertension (95% CI 1.340--1.884, *P* \< 0.001), BMI (95% CI 1.029--1.074, *P* \< 0.001), and albuminuria (95% CI 1.313--1.839, *P* \< 0.001). HbA1c (95% CI 0.825--0.963, *P* = 0.003) and regular alcohol intake (95% CI 0.526--0.767, *P* \< 0.001) were negatively related to renal dysfunction (Table [5](#jdi13116-tbl-0005){ref-type="table"}).

###### 

Factors related to micro‐ and macroalbuminuria and low estimated glomerular filtration rate in patients with type 2 diabetes

  Variable                                   Micro/microalbuminuria[†](#jdi13116-note-0006){ref-type="fn"}   eGFR \<60 mL/min/1.73 m^2^ [‡](#jdi13116-note-0006){ref-type="fn"}                                              
  ------------------------------------------ --------------------------------------------------------------- -------------------------------------------------------------------- --------- --------- ---------------------- ---------
  Sex (men)                                  3.117                                                           1.138 (0.986--1.315)                                                 0.077     19.268    1.517 (1.260--1.828)   \<0.001
  Age (years)                                5.734                                                           1.011 (1.002--1.020)                                                 0.017     128.112   1.075 (1.062--1.089)   \<0.001
  Duration of diabetes (years)               22.315                                                          1.019 (1.011--1.027)                                                 \<0.001   9.856     1.016 (1.006--1.026)   0.002
  Past history or presence of dyslipidemia   0.377                                                           1.041 (0.916--1.182)                                                 0.539     7.978     1.268 (1.075--1.495)   0.005
  Past history or presence of hypertension   57.371                                                          1.659 (1.455--1.892)                                                 \<0.001   28.346    1.589 (1.340--1.884)   \<0.001
  Regular alcohol intake (%)                 0.086                                                           1.022 (0.886--1.179)                                                 0.769     22.171    0.635 (0.526--0.767)   \<0.001
  Smoker, past or current (%)                0.284                                                           0.966 (0.850--1.098)                                                 0.594     0.007     1.007 (0.854--1.187)   0.935
  BMI (kg/m^2^)                              33.314                                                          1.051 (1.033--1.069)                                                 \<0.001   20.146    1.051 (1.029--1.074)   \<0.001
  HbA1c (%)                                  71.584                                                          1.234 (1.175--1.295)                                                 \<0.001   8.605     0.891 (0.825--0.963)   0.003
  eGFR \<60 mL/min/1.73 m^2^                 25.440                                                          1.539 (1.301--1.819)                                                 \<0.001   ND        ND                     ND
  Micro‐ or macroalbuminuria                 ND                                                              ND                                                                   ND        26.324    1.554 (1.313--1.839)   \<0.001

^†^Versus normoalbuminuria. ^‡^Versus estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m^2^. BMI, body mass index; HbA1c, glycated hemoglobin; ND, not done.
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The factors related to renal dysfunction in normoalbuminuric patients with type 1 and type 2 diabetes by logistic regression model are shown in Tables[ S3](#jdi13116-sup-0001){ref-type="supplementary-material"} and [S4](#jdi13116-sup-0001){ref-type="supplementary-material"}. Only age (95% CI 1.069--1.218, *P* \< 0.001) was positively related to low eGFR in normoalbuminuric patients with type 1 diabetes ([Table S3](#jdi13116-sup-0001){ref-type="supplementary-material"}). Factors positively related to renal dysfunction in normoalbuminuric patients with type 2 diabetes were male sex (95% CI 1.046--1.672, *P* = 0.020), age (95% CI 1.067--1.101, *P* \< 0.001), past history or presence of hypertension (95% CI 1.152--1.765, *P* = 0.001) and BMI (95% CI 1.036--1.095, *P* \< 0.001). Regular alcohol intake (95% CI 0.514--0.835, *P* = 0.001) was negatively related to low eGFR ([Table S4](#jdi13116-sup-0001){ref-type="supplementary-material"}).

We further assessed if the incidence rate of low eGFR with normoalbuminuria is related to increased prescription of ACE inhibitor or ARB. As shown in [Table S5](#jdi13116-sup-0001){ref-type="supplementary-material"}, age (95% CI 1.058--1.197, *P* \< 0.001) was positively related to renal dysfunction in normoalbuminuric patients with type 1 diabetes; however, there was no significant relationship between the use of ACE inhibitor or ARB and renal dysfunction. Factors positively related to renal dysfunction in normoalbuminuric patients with type 2 diabetes were male sex (95% CI 1.021--1.629, *P* = 0.033), age (95% CI 1.070--1.104, *P* \< 0.001) and BMI (95% CI 1.042--1.101, *P* \< 0.001), but not the use of ACE inhibitor or ARB. Regular alcohol intake (95% CI 0.525--0.851, *P* = 0.001) was negatively related to low eGFR ([Table S6](#jdi13116-sup-0001){ref-type="supplementary-material"}).

Discussion {#jdi13116-sec-0011}
==========

We analyzed the incidence rate of albuminuria and renal dysfunction, and related factors in patients with diabetes using baseline data of the JDCP study. The incidence rate of microalbuminuria in type 2 diabetes patients was 25.0%, and that of macroalbuminuria was 5.1%. Previously, Mogensen reported that approximately 30% of patients with diabetes progress to microalbuminuria at 15 years from the onset[9](#jdi13116-bib-0009){ref-type="ref"}. The incidence of microalbuminuria was approximately 2% per year, and the prevalence was 25% at 10 years and 38% at 15 years after diagnosis of type 2 diabetes in the United Kingdom Prospective Disease Study^10^. Parving *et al*.[11](#jdi13116-bib-0011){ref-type="ref"} reported that the incidence rate of normoalbuminuria, microalbuminuria and macroalbuminuria was 51%, 39% and 10%, respectively, in the cohort of type 2 diabetes patients in 33 countries worldwide. The prevalence in Asian diabetes patients was reported to be 40% in the MicroAlbuminuria Prevalence study[12](#jdi13116-bib-0012){ref-type="ref"}. The incidence rate of microalbuminuria in the current study is much lower as compared with these previous studies, suggesting that the prognosis of type 2 diabetes has recently been improving[13](#jdi13116-bib-0013){ref-type="ref"}. As for Japanese diabetes patients, the Japan Diabetes Clinical Data Management (JDDM) study reported that the incidence rate of microalbuminuria was 32% in 8,897 Japanese patients with type 2 diabetes[14](#jdi13116-bib-0014){ref-type="ref"}. The patients were registered from 2004 to 2005, the average age and duration of diabetes were 63 and 12 years, respectively, in the JDDM study. In contrast, the patients were registered from 2007 to 2011, and the average age and duration were 61 and 11 years, respectively, in the JDCP study. The average HbA1c was higher in the JDCP study (7.4%) as compared with the JDDM study (7.1%). The difference between these two studies suggests that the rate of development of nephropathy has been decreasing in Japanese patients with type 2 diabetes; however, it might be caused by the difference of age or disease duration.

The proportion of renal dysfunction (eGFR \<60 mL/min/1.73 mm^2^) was 15.3% in type 2 diabetes patients in the present study. The United Kingdom Prospective Disease Study reported that deterioration of GFR (eGFR \<60 mL/min/1.73 mm^2^) occurred in 29% of the participants after 15 years from the diagnosis[10](#jdi13116-bib-0010){ref-type="ref"}. In the JDDM study, the prevalence of low eGFR (\<60 mL/min/1.73 mm^2^) was 11% (in JDDM10)[14](#jdi13116-bib-0014){ref-type="ref"} and 15.3% (in JDDM15)[15](#jdi13116-bib-0015){ref-type="ref"}, which is similar to the present result. The proportion of patients with low eGFR (eGFR \<60 mL/min/1.73 m^2^) with normoalbuminuria was 9.0% in total patients, and 12.9% in type 2 diabetes patients with normoalbuminuria. These values are also similar to the results from the JDDM study (7.9% and 11.4%, respectively; JDDM15).

Recently, it has been reported that the incidence rate of low eGFR with normoalbuminuria has been increasing. The rate of progression to end‐stage renal disease is lower in diabetes patients with low eGFR without proteinuria than in patients with proteinuria, although low eGFR is an important risk indicator of cardiovascular diseases[16](#jdi13116-bib-0016){ref-type="ref"}, [17](#jdi13116-bib-0017){ref-type="ref"}. Previous papers reported that 30--50% of patients with type 2 diabetes associated with low GFR were non‐proteinuric[10](#jdi13116-bib-0010){ref-type="ref"}, [18](#jdi13116-bib-0018){ref-type="ref"}. The differences of race and ethnicity were reported in the incidence rate of renal disease in diabetes patients[19](#jdi13116-bib-0019){ref-type="ref"}, [20](#jdi13116-bib-0020){ref-type="ref"}. Recently, Bhalla *et al*.[21](#jdi13116-bib-0021){ref-type="ref"} reported that there are significant differences in the incidence rate of proteinuric diabetic renal injury among different ethnic groups using electronic health data in northern California in the USA.

The common related factors to albuminuria and renal dysfunction in patients with type 2 diabetes were age, duration of diabetes, past history or presence of hypertension and BMI. HbA1c was positively related to albuminuria and negatively related to low eGFR. Fasting and postprandial blood glucose levels were higher in albuminuric patients and lower in patients with low eGFR. The current results suggest that hyperglycemia affects glomerular and/or tubular functions through various mechanisms, including hemodynamic change resulting in albuminuria. In contrast, renal dysfunction might lower the blood glucose level through a change of insulin turn over and a decrease in gluconeogenesis in the kidney. Male sex and dyslipidemia were related to low eGFR, but not to albuminuria, suggesting that the factors associated with atherosclerosis contribute to renal dysfunction in addition to the common risk factors. Interestingly, regular alcohol intake was negatively related to renal dysfunction, although the reason remains unclear. The United Kingdom Prospective Disease Study reported that female sex, older age and insulin resistance were risk factors for low GFR, but not for albuminuria, whereas male sex, hyperglycemia, hyperlipidemia and obesity were risk factors for microalbuminuria, but not for low GFR[10](#jdi13116-bib-0010){ref-type="ref"}. Some these data are different from the results of the JDCP and the JDDM, although the reason is unknown. In the present study, we could not determine the causal relationship between each clinical parameter and renal disease in diabetes patients, because the current results were obtained from the cross‐sectional data of the baseline in the JDCP study. The follow‐up data from the JDCP study will clarify the contributing clinical factors to albuminuria and renal dysfunction.

Factors positively related to renal dysfunction in normoalbuminuric patients with type 2 diabetes were male sex, hypertension and BMI, although use of ACE inhibitor or ARB was not related to low eGFR without albuminuria. These findings suggest that hypertension and obesity might contribute to renal dysfunction in normoalbuminuric patients with type 2 diabetes.

In patients with type 1 diabetes, the prevalence of microalbuminuria and renal dysfunction were 15.2% and 9.9%, respectively. It was reported that incidence rate of microalbuminuria in patients with type 1 diabetes was 27.2% and 25.4% in the two studies carried out in Europe[22](#jdi13116-bib-0022){ref-type="ref"}, [23](#jdi13116-bib-0023){ref-type="ref"}, [24](#jdi13116-bib-0024){ref-type="ref"}. Common risk factors for microalbuminuria and macroalbuminuria were disease duration, HbA1c and dyslipidemia. Blood pressure was a risk factor for microalbuminuria, and male sex was positively related to macroalbuminuria. The prevalence of microalbuminuria in the present study was much lower as compared with the previous studies. It might be possible that the disease duration of the present participants was much shorter than in the other previous studies, although recent epidemiological studies have shown that the prevalence of nephropathy and end‐stage renal disease are decreasing[20](#jdi13116-bib-0020){ref-type="ref"}. The current results suggest that disease duration, hypertension and hyperglycemia contribute to the development of nephropathy in patients with type 1 diabetes. We could not determine whether there is any difference in the associated factors of nephropathy between type 1 and type 2 diabetes, because the present study is cross‐sectional and the sample size of patients with type 1 diabetes is relatively small.

In the present study, we showed the recent prevalence of albuminuria and renal dysfunction, and related factors in Japanese patients with diabetes using the baseline data of the JDCP study. The current results suggest that renal disease in patients with type 2 diabetes is heterogeneous, and there might be different factors contributing to albuminuria and the deterioration of renal function. The prospective follow‐up data of the JDCP study will clarify the causal relationships between the clinical factors and progression or regression of diabetic kidney disease.
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